PROCEPT BioRobotics (NASDAQ: PRCT) is poised to announce its financial results for the fourth quarter of 2025 after market closure on February 24, 2026. Analysts anticipate that the company will report an earnings loss of ($0.32) per share along with quarterly revenues reaching $93.704 million. Investors and interested parties can access the details of the earnings call scheduled for 4:30 PM ET on the same day.
Stock Performance and Financial Ratios
On the day of the announcement, PRCT shares opened at $27.79. The company demonstrates a solid financial foundation with a quick ratio of 7.20, a current ratio of 8.44, and a low debt-to-equity ratio of 0.14. With a market capitalization of $1.55 billion, PROCEPT BioRobotics has experienced a 12-month share price range with a low of $26.66 and a high of $70.80. Current moving averages indicate a 50-day simple moving average of $31.48 and a 200-day simple moving average of $34.50.
Analyst Ratings and Hedge Fund Activity
Recent reports from several research analysts have provided insights into the stock’s performance. On November 5, Leerink Partners maintained an “outperform” rating and set a price target of $55.00. Conversely, Wells Fargo & Company adjusted its price target downwards from $58.00 to $51.00, continuing to rate the stock as “overweight.”
In a notable shift, Wall Street Zen upgraded the stock from “sell” to “hold” on January 10. Similarly, TD Cowen lowered its price objective from $85.00 to $50.00, but maintained a “buy” rating. UBS Group initiated coverage on December 12 with a “buy” rating and a target price of $62.00.
The consensus rating for PROCEPT BioRobotics currently stands at “Moderate Buy,” with an average price target of $53.40 according to MarketBeat data. Out of 13 analysts, one has rated the stock as a Strong Buy, nine have issued Buy ratings, two have assigned Hold ratings, and one has given a Sell rating.
Institutional investors have shown significant interest in PROCEPT BioRobotics, with hedge funds actively trading shares. AQR Capital Management LLC increased its stake by 7.3% during the first quarter, now owning 18,892 shares valued at approximately $1.1 million. UBS Asset Management Americas LLC also raised its position by 9.9%, acquiring an additional 13,767 shares for a total of 153,158 shares worth around $8.9 million.
Intech Investment Management LLC expanded its holdings by 54.4%, while Prudential Financial Inc. doubled its stake by 100.4%, acquiring a total of 6,815 shares. Additionally, State Street Corp increased its holdings by 6.9%, now owning over 1.2 million shares valued at more than $73 million. Overall, institutional and hedge fund investors control approximately 89.46% of the company’s stock.
Company Overview
PROCEPT BioRobotics specializes in the development and commercialization of robotic systems focused on the treatment of benign prostatic hyperplasia (BPH). The company’s innovative technology utilizes precision robotics and real-time imaging to perform minimally invasive procedures, aiming to enhance patient recovery times and improve clinical outcomes compared to traditional surgical methods. The flagship product, the AquaBeam Robotic System, employs a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
As the earnings call approaches, stakeholders will be keenly observing the company’s performance metrics and future growth prospects in the fast-evolving medical device sector.
